Joshua Schimmer
Stock Analyst
(n/a)
# 2,872
Out of 4,648 analysts
27
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Joshua Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio | Reiterates: Overweight | $50 | $4.00 | +1,151.56% | 4 | Apr 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Reiterates: Overweight | $50 | $40.67 | +22.96% | 2 | Nov 15, 2023 | |
| OTIS Otis Worldwide | Maintains: Equal-Weight | $91 → $92 | $99.51 | -7.55% | 4 | Jul 27, 2023 | |
| RNA Avidity Biosciences | Downgrades: In-Line | $20 | $45.16 | -55.71% | 1 | Mar 31, 2023 | |
| BNOX Bionomics | Upgrades: Outperform | $6 | $0.20 | +2,976.92% | 2 | Mar 10, 2023 | |
| NBIX Neurocrine Biosciences | Upgrades: Outperform | $130 | $120.28 | +8.08% | 1 | Mar 3, 2023 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $80 → $50 | $27.50 | +81.82% | 1 | Feb 28, 2023 | |
| TGTX TG Therapeutics | Maintains: Outperform | $16 → $25 | $24.15 | +3.54% | 3 | Jan 24, 2023 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $65 → $75 | $16.95 | +342.61% | 1 | Sep 30, 2022 | |
| BMRN BioMarin Pharmaceutical | Upgrades: Outperform | $90 → $100 | $66.24 | +50.97% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $831.69 | - | 2 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $86 → $100 | $0.46 | +21,530.98% | 2 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $75.77 | +12.18% | 3 | May 31, 2018 |
Cabaletta Bio
Apr 5, 2024
Reiterates: Overweight
Price Target: $50
Current: $4.00
Upside: +1,151.56%
Mirum Pharmaceuticals
Nov 15, 2023
Reiterates: Overweight
Price Target: $50
Current: $40.67
Upside: +22.96%
Otis Worldwide
Jul 27, 2023
Maintains: Equal-Weight
Price Target: $91 → $92
Current: $99.51
Upside: -7.55%
Avidity Biosciences
Mar 31, 2023
Downgrades: In-Line
Price Target: $20
Current: $45.16
Upside: -55.71%
Bionomics
Mar 10, 2023
Upgrades: Outperform
Price Target: $6
Current: $0.20
Upside: +2,976.92%
Neurocrine Biosciences
Mar 3, 2023
Upgrades: Outperform
Price Target: $130
Current: $120.28
Upside: +8.08%
Denali Therapeutics
Feb 28, 2023
Maintains: Outperform
Price Target: $80 → $50
Current: $27.50
Upside: +81.82%
TG Therapeutics
Jan 24, 2023
Maintains: Outperform
Price Target: $16 → $25
Current: $24.15
Upside: +3.54%
Rocket Pharmaceuticals
Sep 30, 2022
Maintains: Outperform
Price Target: $65 → $75
Current: $16.95
Upside: +342.61%
BioMarin Pharmaceutical
Mar 1, 2021
Upgrades: Outperform
Price Target: $90 → $100
Current: $66.24
Upside: +50.97%
Feb 25, 2020
Upgrades: Outperform
Price Target: n/a
Current: $831.69
Upside: -
Feb 3, 2020
Upgrades: Outperform
Price Target: $86 → $100
Current: $0.46
Upside: +21,530.98%
May 31, 2018
Assumes: Overweight
Price Target: $85
Current: $75.77
Upside: +12.18%